ETM Experimental and Therapeutic Medicine 1792-0981 1792-1015 D.A. Spandidos 10.3892/etm.2017.5326 ETM-0-0-5326 Articles Expression of the deubiquitinase cylindromatosis in articular cartilage and subchondral bone is associated with the severity of knee osteoarthritis HongLiu 1 * ShanjiangYu 1 * QianWang 1 ChunguoLi 1 FeiZhou 1 JinmingYu 1 JiyouGao 2 NaLi 2 YangLi 3 FengDu 1 Department of Orthopedics, People's Hospital of Linzi, Zibo, Shandong 255400, P.R. China Department of Orthopedics, Shandong Provincial Hospital, Jinan, Shandong 250021, P.R. China Department of Orthopedics, Central Hospital of Zibo Mining Group, Zibo, Shandong 255120, P.R. China Correspondence to: Dr Du Feng, Department of Orthopedics, People's Hospital of Linzi, 139 Huan Gong Road, Linzi, Zibo, Shandong 255400, P.R. China, E-mail: dufengzblz1982@126.com

Contributed equally

 12 2017 18 10 2017 14 6 5990 5996 09052017 01092017 Copyright: © Hong et al. 2017 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Cylindromatosis (CYLD) is a deubiquitinating enzyme that regulates multiple key signaling pathways involved in the pathophysiology of knee osteoarthritis (KOA). Previous studies have indicated that the expression of CYLD in the articular cartilage of patients with KOA is significantly higher than in healthy controls. However, limited data are available regarding the association between CYLD expression and the severity of KOA. The aim of the present study was to investigate the association between CYLD expression in joint tissues and the severity of KOA. A total of 156 individual tibial plateau samples were obtained between January 2011 and January 2016 from patients that had undergone total knee arthroplasty due to KOA or from healthy controls. The severity of KOA was evaluated using the Kellgren Lawrence (KL) and Mankin scoring systems. Additionally, CYLD expression in the articular cartilage and subchondral bone was analyzed using immunohistochemistry. Compared with the healthy controls, patients with KOA exhibited significantly increased CYLD levels in the articular cartilage (6.53±2.01 vs. 28.69±13.23, P<0.001) and significantly decreased CYLD levels in the subchondral bone (11.46±2.34 vs. 3.50±2.54, P<0.001). Correlation analysis indicated that CYLD expression in the articular cartilage was positively correlated with the KL (r=0.837, P<0.001) and Mankin scores (r=0.925, P<0.001), while its expression in the subchondral bone was negatively correlated with the KL (r=−0.802, P<0.001) and Mankin scores (r=−0.844, P<0.001). The results of the present study demonstrate that CYLD levels in the articular cartilage and subchondral bone are associated with the severity of KOA. Thus, CYLD may be a potential diagnostic and predictive biomarker for KOA and a novel target in its treatment.

 cylindromatosis articular cartilage subchondral bone knee osteoarthritis biomarker Introduction

Knee osteoarthritis (KOA) is a common type of joint disease that affects the whole joint, including the articular cartilage, synovial membrane, meniscus and subchondral bone (1). It is characterized by progressive articular cartilage degradation, subchondral bone sclerosis, osteophyte formation and under-mineralization of the trabecular structure (2,3). The precise underlying mechanism responsible for KOA remains poorly understood but it is widely accepted that biochemical and biomechanical factors serve important roles in the pathogenesis of KOA (4–6).

Over the past two decades, studies investigating KOA have focused on bodily fluid biomarkers, tissue biomarkers and novel drug targets (7–12). Previous studies have demonstrated that the receptor activator of nuclear factor-κB (RANK) signaling pathway, transforming growth factor β1 (TGF-β1) pathway and nuclear factor-κB pathway are all associated with KOA progression (13–15). Additionally, Wnt inhibitory factor-1 (9), hypoxia-inducible factor-1α (10), osteopontin and Wnt5a (12) are associated with the severity of KOA.

Cylindromatosis (CYLD) is a deubiquitinating enzyme that has broad regulative effects on KOA, including its negative regulation of the RANK (16) and TGF-β1 signaling pathways (13,17). Furthermore, CYLD is a crucial negative regulator of osteoclastogenesis (16). Given the roles of the aforementioned signaling pathways in articular cartilage degradation and the subchondral bone remodeling processes, it was hypothesized that the expression of CYLD in the articular cartilage and subchondral bone may be associated with KOA severity.

It has been reported that levels of CYLD mRNA in the articular cartilage of patients with KOA are two-times higher than those in the articular cartilage of healthy controls (18). However, limited data are available regarding the expression of CYLD in other joint tissues and on the association between CYLD expression in joint tissues and the severity of KOA. Thus, the aim of the present study was to analyze the expression patterns of CYLD in different sections of the knee joint in patients with KOA to evaluate its potential association with the severity of KOA.

 Patients and methods <sec> <title>Patients

The protocol of the current study was approved by the Ethics Committees of Shandong Provincial Hospital (Jinan, China), the People's Hospital of Linzi (Linzi, China) and the Central Hospital of Zibo Mining Group (Zibo, China). Human tibial plateau (TP) samples were retrospectively collected from 129 patients with KOA that underwent primary total knee arthroplasty due to KOA and 27 healthy controls who underwent primary amputation due to severe lower-extremity trauma between January 2011 and January 2016. All participants were enrolled from the aforementioned three hospitals. Patients with KOA were diagnosed according to the criteria of the American College of Rheumatology (19). All patients and healthy controls enrolled in the study had signed legally effective informed consent forms. None of the enrolled subjects had a history of bone tumors, conditions affecting bone remodeling, including rheumatoid arthritis, osteoporosis, renal osteopathy or thyroid disease, or use of drugs that affect bone metabolism. The Kellgren Lawrence (KL) score was used to indicate the severity of KOA and this was determined based on knee joint radiographs (20).

 Histological analysis

TPs were harvested during surgery, washed with normal saline to remove excess blood, wrapped with gauze and frozen at −70°C. Samples were removed from storage 48 h prior to use and thawed for 24 h at 4°C and 24 h at room temperature. For each TP, 9 samples were harvested from the medial, central and lateral regions, respectively, at a depth of 1.0 cm (~0.3×0.3×1.0 cm). A total of 3 samples were harvested from each region. Samples were then fixed in 4% paraformaldehyde at room temperature for 24 h, decalcified in 10% EDTA and dehydrated in graded ethanol. Following dehydration, samples were embedded in paraffin, cut into 5-µm-thick sections, placed on 3-aminopropyltriethoxy-silane coated slides and stored at 4°C. Hematoxylin and eosin staining and safranin O staining were performed following previously published protocols (21).

Following histological staining, the severity of articular cartilage damage was classified into four categories based on the following modified Mankin system: Grade I (Mankin score, 0–1); grade II (Mankin score, 2–5); grade III (Mankin score, 6–9); and grade IV (Mankin score, ≥10) (22).

 Immunohistochemistry

Immunohistochemical staining was performed to assess the expression of CYLD in TP samples using Histostain-SP kits (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) (23). Fixed paraffin-embedded samples were heated at 60°C for 30 min, deparaffinized in xylene (10 min × 2), rehydrated in alcohol (100% alcohol for 5 min × 2, 95% alcohol for 5 min × 2, and 85, 75 and 50% alcohol for 5 min each), and washed with distilled water and PBS for 5 min each. The samples were then treated successively with 3% H2O2 in methanol at room temperature for 10 min and 20% goat serum (both Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) at room temperature for 30 min to block endogenous peroxidase activity and nonspecific antibody binding. Subsequently, sections were incubated with diluted rabbit polyclonal anti-CYLD antibody (1:100; cat. no. ab137524; Abcam, Cambridge, UK) at 37°C for 2 h, then with goat anti-rabbit immunoglobulin G (1:1,000; cat. no. A0545; Sigma-Aldrich; Merck KGaA) at 37°C for 30 min. Finally, samples were stained with diaminobenzidine tetrachloride at room temperature for 8 min and counterstained with hematoxylin at room temperature for 1 min. Sections prepared using PBS instead of primary antibody were used as negative controls. All the sections were examined by a blinded independent pathologist using a BX51 microscope (Olympus Corporation, Tokyo, Japan) at a magnification of ×100.

CYLD levels were expressed as normalized optical density (OD) values and were determined using a MetaMorph/DPIO/BX41 morphology image analysis system (Olympus Corporation). PBS was used for OD normalization and the experiment was repeated in triplicate. The variation coefficients of CYLD expression in the articular cartilage and subchondral bone were <2%.

 Statistical analyses

Data were analyzed using SPSS 17.0 (SPSS, Inc., Chicago, IL, USA). Normally distributed measurement data were expressed as the mean ± standard deviation. Data were compared using one-way analysis of variance with a Tukey's honest significant difference post hoc test or t-tests. Skewed measurement data were expressed as the median and interquartile range and compared using Mann-Whitney U-tests. Numerical data were expressed as percentages and differences between groups were compared using the Pearson's χ2 test. Associations between CYLD expression in TP samples and the severity of KOA were analyzed using Spearman's correlation analysis. P<0.05 was considered to indicate a statistically significant difference.

 Results <sec> <title>Patient characteristics

A total of 156 participants were enrolled in the present study. Baseline features of the patients that may have been associated with the severity of articular cartilage degeneration are listed in Table I. No significant differences were identified in the age, sex or body mass index between healthy controls and patients with KOA (P>0.05). KL and Mankin scores of the patients with KOA from three hospitals are listed in Table II. Disease severity did not differ significantly among the patients from the different hospitals (P>0.05).

 Expression of CYLD in different TP regions

CYLD expression in the TP samples was detected by immunohistochemistry and was determined using normalized OD values. As presented in Table III, CYLD expression in the articular cartilage of patients with KOA was significantly higher than that of the healthy controls (t=8.66, P<0.001). By contrast, CYLD expression in the subchondral bone of patients with KOA was significantly lower than in the healthy controls (t=−15.004, P<0.001).

Representative immunohistochemical staining images and radiographs of the TP samples are presented in Fig. 1. Immunohistochemistry detected CYLD expression in the cell nuclei and cytoplasm; regions with positive CYLD immunostaining were indicated by dark brown granular staining (Fig. 1A and B). Safranin O stained sections revealed that the degree of cartilage destruction was positively associated with the severity of KOA (Fig. 1C). Radiographs of the KOA patients identified clear narrowing of the joint space, which was also positively associated with the severity of KOA (Fig. 1D). As shown in Fig. 1A compared with Fig. 1C and D, elevated CYLD expression in the articular cartilage of patients with KOA was concomitant with the severity of KOA. The opposite pattern of CYLD expression was observed in the subchondral bone of patients with KOA, which was demonstrated in Fig. 1B compared with Fig. 1C and D.

 Association between CYLD expression and KL score

KL scores of all patients with KOA were >III, which was in accordance for what is expected in patients requiring total knee replacement. The potential association between CYLD expression in the TP samples and KL score was analyzed by Spearman's correlation analysis. The results are presented in Table IV and indicate that the expression of CYLD in the articular cartilage was positively correlated with the KL score (r=0.837, P<0.001), and that CYLD expression in the subchondral bone was negatively correlated with the KL score (r=−0.802, P<0.001).

 Associations between CYLD expression and Mankin score

Articular cartilage sections were classified using modified Mankin scores. As presented in Table V, the articular cartilage sections classified as grades I, II, III and IV exhibited CYLD expression of 6.53±2.01, 14.23±4.66, 21.13±5.13 and 38.91±10.82%, respectively. CYLD expression in the corresponding graded subchondral bone sections of TP samples were 11.46±2.34, 7.81±1.66, 3.97±1.41 and 1.73±1.17%, respectively.

Spearman's correlation analysis was conducted to assess the association between CYLD expression and Mankin scores. The results indicated that CYLD expression in the articular cartilage and subchondral bone was significantly correlated with the Mankin score (r=0.925 and r=−0.844, all P<0.001). Scatter diagrams were used to plot the correlation between CYLD expression and Mankin score for the TP samples (Fig. 2) and demonstrated that an increased Mankin score is correlated with increased CYLD expression in the articular cartilage and reduced CYLD expression in the subchondral bone.

 Discussion

The present study may represent the first attempt to systematically evaluate CYLD expression in the TP tissue of patients with KOA and determine its association with the severity of KOA. KL and Mankin scores were used to grade the severity of knee OA and the expression of CYLD in the articular cartilage and subchondral bone was determined by immunohistochemistry. Notably, it was determined that CYLD expression was significantly increased in the articular cartilage but significantly reduced in the subchondral bone of patients with KOA. Although there are very few published studies investigating the expression of CYLD in TP tissue, the results of certain reports are partially consistent with those of the current study. Song et al (18) reported that CYLD expression in the articular cartilage of patients with KOA was significantly higher than in healthy controls.

Progressive articular cartilage degradation and subchondral bone sclerosis are typical pathological changes that occur in KOA. Despite extensive investigations into the sequence of these pathological changes, a generally accepted mechanism has yet to be established (24–28). However, an increasing number of studies have demonstrated that there is molecular crosstalk between the articular cartilage and subchondral bone (28–31). In the present study, it was identified that the expression of CYLD in the articular cartilage was positively correlated with the KL (r=0.837, P<0.001) and Mankin scores (r=0.925, P<0.001), whereas CYLD expression in the subchondral bone was negatively correlated with KL (r=−0.802, P<0.001) and Mankin scores (r=−0.844, P<0.001). These results indicate that CYLD expression may be a potential biomarker for the diagnosis of KOA, as well for monitoring the severity of KOA. Changes in the expression of CYLD may be an early event involved in the pathological processes of articular cartilage degradation and subchondral bone remodeling abnormalities. Additionally, CYLD may serve a crucial role in the molecular crosstalk that occurs between the articular cartilage and subchondral bone in KOA.

Several signaling pathways have been implicated in the molecular crosstalk between articular cartilage and subchondral bone, including the TGF-β and Wnt signaling pathways (28–31). CYLD may negatively regulate these signaling pathways during the pathological processes of KOA (16,17). This may explain why CYLD expression is increased in the articular cartilage but decreased in the subchondral bone of patients with KOA and may explain its correlation with the severity of KOA.

TGF-β also exhibits inverse expression trends in KOA; its expression is decreased in the articular cartilage and increased in the subchondral bone (29,32,33). Furthermore, inhibition of TGF-β expression in the articular cartilage or upregulation of TGF-β expression in the subchondral bone aggravates the degeneration of articular cartilage (32). CYLD negatively regulates TGF-β expression by deubiquitinating protein kinase B (17). Elevated Wnt signaling may also induce bone sclerosis (34) and this may be associated with the reduced deubiquitinating activity of CYLD (35). Additionally, decreased CYLD expression in the subchondral bone may induce subchondral bone remodeling abnormalities via negative regulation of the RANK signaling pathway (16). Collectively, the aforementioned findings support the hypothesis that CYLD exhibits regulatory activity during the processes of articular cartilage degradation and subchondral bone remodeling in KOA. However it remains unknown whether the articular cartilage and subchondral bone influence each other via CYLD expression. Further studies are required to elucidate the precise mechanisms of CYLD in KOA, particularly regarding its potential effects on osteoblasts, osteoclasts and chondrocytes.

The sample size of the present study was larger than that of previous studies (9,12), and in the present study, TP samples were collected from subjects admitted to three different public hospitals, including one 2A hospital, one 3B hospital and one 3A hospital. Hospitals in China are classified into 9 grades according to the size of the hospital, medical technology, medical equipment, management and medical quality; they are as follows: 1A, 1B, 1C, 2A, 2B, 2C, 3A, 3B and 3C. Hospitals grades as 1A, 1B and 1C are township hospitals, which provide preventive care and minimal health care. Hospitals grades as 2A, 2B, 2C, 3A, 3B and 3C are affiliated with large and medium-sized cities, and responsible for providing specialist health services. Most Chinese patients with mild and moderate-severe diseases tend to choose large hospitals, including 2A, 3A, 3B and 3C hospitals, for specialist treatment (36). This means that samples included in the present study were more likely to be representative of all patients with KOA. Nevertheless, the present study still had a number of limitations. The current study was retrospective; thus, the collection of blood or synovial fluid samples from patients was not possible. Given that biomarkers included in the bodily fluid are more favorable for diagnosis (37), further studies are required to investigate the associations between CYLD levels in bodily fluids and the severity of KOA, which may assist the early diagnosis and estimations of prognosis in patients. Furthermore, KL and Mankin scores are artificial classification systems used for grading the severity of KOA. The KL score is considered to be imprecise and indefinite (37,38) and neither of these classification systems fully reflect the severity of subchondral bone remodeling abnormalities. Therefore, more detailed studies are necessary to investigate the associations between CYLD levels in TP tissues, and the activities of osteoblasts, osteoclasts and chondrocytes.

In conclusion, despite these limitations, the present study demonstrated that CYLD levels in the articular cartilage and subchondral bone of patients with KOA were associated with the severity of KOA. Thus, CYLD may be a potential diagnostic and predictive biomarker for KOA.

 Acknowledgements

The present study was supported by the National Natural Science Foundation of China (grant no. 30973040) and the Natural Science Foundation of Shandong Province (grant no. 2012ZRB127AO).

 Abbreviations CYLD

cylindromatosis

 KOA

knee osteoarthritis

 TP

tibial plateau

 KL

Kellgren Lawrence

 RANK

receptor activator of nuclear factor-κB

 TGF-β1

transforming growth factor β1

 TP

tibial plateau

 References HeidariBKnee osteoarthritis prevalence, risk factors, pathogenesis and features: Part ICaspian J Intern Med2205212201124024017 ManGSMologhianuGOsteoarthritis pathogenesis-a complex process that involves the entire jointJ Med Life73741201424653755 HayamiTOsteoarthritis of the knee joint as a cause of musculoskeletal ambulation disability symptom complex (MADS)Clin Calcium18157415802008(In Japanese)18974445 GuilakFBiomechanical factors in osteoarthritisBest Pract Res Clin Rheumatol25815823201110.1016/j.berh.2011.11.01322265263 PowellATeichtahlAJWlukaAECicuttiniFMObesity: A preventable risk factor for large joint osteoarthritis which may act through biomechanical factorsBr J Sports Med3945200510.1136/bjsm.2004.01184115618330 FukuiNIkedaYOhnukiTTanakaNHikitaAMitomiHMoriTJujiTKatsuragawaYYamamotoSRegional differences in chondrocyte metabolism in osteoarthritis: A detailed analysis by laser capture microdissectionArthritis Rheum58154163200810.1002/art.2317518163492 HunterDJNevittMLosinaEKrausVBiomarkers for osteoarthritis: Current position and steps towards further validationBest Pract Res Clin Rheumatol286171201410.1016/j.berh.2014.01.00724792945 AtturMKrasnokutsky-SamuelsSSamuelsJAbramsonSBPrognostic biomarkers in osteoarthritisCurr Opin Rheumatol25136144201310.1097/BOR.0b013e32835a938123169101 GaoSGZengCLiuJJTianJChengCZhangFJXiongYLPanDXiaoYBLeiGHAssociation between Wnt inhibitory factor-1 expression levels in articular cartilage and the disease severity of patients with osteoarthritis of the kneeExp Ther Med1114051409201610.3892/etm.2016.304927073457 QingLLeiPLiuHXieJWangLWenTHuYExpression of hypoxia-inducible factor-1α in synovial fluid and articular cartilage is associated with disease severity in knee osteoarthritisExp Ther Med136368201710.3892/etm.2016.394028123469 Al-JarallahKFShehabDAl-AwadhiANaharIHaiderMZMoussaMAAre 25(OH)D levels related to the severity of knee osteoarthritis and function?Med Princ Pract217478201210.1159/00033002522024977 LiYXiaoWSunMDengZZengCLiHYangTLiLLuoWLeiGThe expression of osteopontin and Wnt5a in articular cartilage of patients with knee osteoarthritis and its correlation with disease severityBiomed Res Int20169561058201627556044 FangJXuLLiYZhaoZRoles of TGF-beta 1 signaling in the development of osteoarthritisHistol Histopathol3111611167201627164863 RigoglouSPapavassiliouAGThe NF-κB signalling pathway in osteoarthritisInt J Biochem Cell Biol4525802584201310.1016/j.biocel.2013.08.01824004831 ZengGQChenABLiWSongJHGaoCYHigh MMP-1, MMP-2, and MMP-9 protein levels in osteoarthritisGenet Mol Res141481114822201510.4238/2015.November.18.4626600542 JinWChangMPaulEMBabuGLeeAJReileyWWrightAZhangMYouJSunSCDeubiquitinating enzyme CYLD negatively regulates RANK signaling and osteoclastogenesis in miceJ Clin Invest11818581866200810.1172/JCI3425718382763 LimJHJonoHKomatsuKWooCHLeeJMiyataMMatsunoTXuXHuangYZhangWCYLD negatively regulates transforming growth factor-β-signalling via deubiquitinating AktNat Commun3771201210.1038/ncomms177622491319 SongJJinEHKimDKimKYChunCHJinEJMicroRNA-222 regulates MMP-13 via targeting HDAC-4 during osteoarthritis pathogenesisBBA Clin37989201410.1016/j.bbacli.2014.11.00926673737 AletahaDNeogiTSilmanAJFunovitsJFelsonDTBinghamCOIIIBirnbaumNSBurmesterGRBykerkVPCohenMD2010 rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiativeArthritis Rheum6225692581201010.1002/art.2758420872595 EdwardsMHParsonsCBruyèreODopPetit FChapurlatRRoemerFWGuermaziAZaimSGenantHReginsterJYHigh kellgren-lawrence grade and bone marrow lesions predict worsening rates of radiographic joint space narrowing; the SEKOIA studyJ Rheumatol43657665201610.3899/jrheum.15005326773120 JaiprakashAPrasadamIFengJQLiuYCrawfordRXiaoYPhenotypic characterization of osteoarthritic osteocytes from the sclerotic zones: A possible pathological role in subchondral bone sclerosisInt J Biol Sci8406417201210.7150/ijbs.422122419886 WeiFZhouJWeiXZhangJFlemingBCTerekRPeiMChenQLiuTWeiLActivation of Indian hedgehog promotes chondrocyte hypertrophy and upregulation of MMP-13 in human osteoarthritic cartilageOsteoarthritis Cartilage20755763201210.1016/j.joca.2012.03.01022469853 WelteSUrbanikTElßnerCKautzNKoehlerBCWaldburgerNBermejoJLPinnaFWeissKHSchemmerPNuclear expression of the deubiquitinase CYLD is associated with improved survival in human hepatocellular carcinomaPLoS One9e110591201410.1371/journal.pone.011059125329885 BurrDBGallantMABone remodelling in osteoarthritisNat Rev Rheumatol8665673201210.1038/nrrheum.2012.13022868925 Anderson-MacKenzieJMQuasnichkaHLStarrRLLewisEJBillinghamMEBaileyAJFundamental subchondral bone changes in spontaneous knee osteoarthritisInt J Biochem Cell Biol37224236200510.1016/j.biocel.2004.06.01615381164 HayamiTPickarskiMZhuoYWesolowskiGARodanGADuongLTCharacterization of articular cartilage and subchondral bone changes in the rat anterior cruciate ligament transection and meniscectomized models of osteoarthritisBone38234243200610.1016/j.bone.2005.08.00716185945 DayJSDingMvan der LindenJCHvidISumnerDRWeinans HA decreased subchondral trabecular bone tissue elastic modulus is associated with pre-arthritic cartilage damageJ Orthop Res19914918200110.1016/S0736-0266(01)00012-211562141 ZhangLZZhengHAJiangYTuYHJiangPHYangALMechanical and biologic link between cartilage and subchondral bone in osteoarthritisArthritis Care Res (Hoboken)64960967201222328172 SharmaARJaggaSLeeSSNamJSInterplay between cartilage and subchondral bone contributing to pathogenesis of osteoarthritisInt J Mol Sci141980519830201310.3390/ijms14101980524084727 YuanXLMengHYWangYCPengJGuoQYWangAYLuSBBone-cartilage interface crosstalk in osteoarthritis: Potential pathways and future therapeutic strategiesOsteoarthritis Cartilage2210771089201410.1016/j.joca.2014.05.02324928319 FindlayDMKuliwabaJSBone-cartilage crosstalk: A conversation for understanding osteoarthritisBone Res416028201610.1038/boneres.2016.2827672480 ShenJLiSChenDTGF-β signaling and the development of osteoarthritisBone Res2pii: 14002201410.1038/boneres.2014.225541594 Van der KraanPMAge-related alterations in TGF beta signaling as a causal factor of cartilage degeneration in osteoarthritisBiomed Mater Eng241 SupplS75S802014 JenkinsZAvan KogelenbergMMorganTJeffsAFukuzawaRPearlEThallerCHingAVPorteousMEGarcia-MiñaurSGermline mutations in WTX cause a sclerosing skeletal dysplasia but do not predispose to tumorigenesisNat Genet4195100200910.1038/ng.27019079258 TaurielloDVHaegebarthAKuperIEdelmannMJHenraatMCanninga-van DijkMRKesslerBMCleversHMauriceMMLoss of the tumor suppressor CYLD enhances Wnt/beta-catenin signaling through K63-linked ubiquitination of DvlMol Cell37607619201010.1016/j.molcel.2010.01.03520227366 LiXHuangJZhangHAn analysis and of hospital preparedness capacity for public health emergency in four regions of China: Beijing, Shandong Guangxi and HainanBMC Public Health8319200810.1186/1471-2458-8-31918803860 GuermaziAHayashiDRoemerFFelsonDTWangKLynchJAminSTornerJLewisCENevittMCSevere radiographic knee osteoarthritis-does Kellgren and Lawrence grade 4 represent end stage disease?-the MOST studyOsteoarthritis Cartilage2314991505201510.1016/j.joca.2015.04.01825929973 SchiphofDBoersMBierma-ZeinstraSMDifferences in descriptions of Kellgren and Lawrence grades of knee osteoarthritisAnn Rheum Dis6710341036200810.1136/ard.2007.07902018198197

Representative staining images and radiographs of TPs. (A) CYLD immunohistochemical staining in the articular cartilage (magnification ×100). (B) CYLD immunohistochemical staining in the subchondral bone (magnification ×100). (C) Safranin O staining of the articular cartilage (magnification ×100). (D) Radiographs of TPs. Grades I–IV: Severity of knee osteoarthritis graded using (A-C) the modified Mankin system or (D) the Kellgren Lawrence system. TP, tibial plateau; CYLD, cylindromatosis.

Associations between CYLD expression in the tibial plateau and the Mankin score. Scatter diagrams indicated that CYLD levels in articular cartilage and subchondral bone were correlated with the severity of knee osteoarthritis. CYLD, Cylindromatosis.

Baseline features of patients.

Parameter n Age [years, M (QR)] Sex (n, % female) BMI (kg/m2, x¯±s)
Control group 27 61.50 (49.00–71.00) 12 (44.4) 25.38±3.55
KOA group 129 63.00 (49.00–71.00) 63 (48.8) 26.89±3.58
χ2/t/z NA −0.203 0.173 1.975
P-value NA   0.839 0.678 0.048

KOA, knee osteoarthritis; M (QR), median (interquartile range); NA, not applicable; BMI, body mass index; x¯±s, mean standard deviation.

Baseline features of patients with knee osteoarthritis from the three different hospitals.

KL scores (n, %) Mankin scores (n, %)
Hospital names n Age (years) Sex (n, % female) BMI (kg/m2) III IV II III IV
SDH 59 65.00 (47.00–72.00) 30 (50.8) 27.14 (21.93–33.72) 13 (22.03) 46 (77.97) 8 (13.56) 18 (30.51) 33 (55.93)
LZH 42 60.00 (48.00–71.00) 19 (45.2) 25.64 (20.86–32.16) 10 (23.81) 32 (76.19) 7 (16.67) 18 (42.86) 17 (40.47)
ZBH 28 64.00 (49.00–71.00) 14 (50.0) 28.24 (23.03–34.32) 7 (25.00) 21 (75.00) 6 (21.43) 9 (32.14) 13 (46.43)
χ2/z NA −1.310 0.328 −1.642   0.104   3.120
P-value NA 0.190 0.849 0.102   0.949   0.538

All values are presented as the median (interquartile range), unless otherwise specified. NA, not applicable; SDH, Shandong Provincial Hospital; LZH, People's Hospital of Linzi; ZBH, Central Hospital of Zibo Mining Group; M (QR), median (interquartile range); BMI, body mass index; KL, Kellgren Lawrence.

Expression of CYLD in the TP of patients with KOA and healthy controls.

CYLD levels (%) Articular cartilage Subchondral bone t P-value
Control group 6.53±2.01 11.46±2.34 8.295 <0.001
KOA group 28.69±13.23 3.50±2.54 21.235 <0.001
t 8.66 −15.004 NA NA
P-value <0.001 <0.001 NA NA

All values are presented as the mean ± standard deviation. CYLD, cylindromatosis; TP, tibial plateau; KOA, knee osteoarthritis; NA, not applicable.

Association between CYLD expression in the TP and KL scores.

CYLD levels (%) I–II III IV r P-value
n 27 30 99 NA NA
Articular cartilage   6.53±2.01 14.22±4.17 33.08±11.83   0.837 <0.001
Subchondral bone 11.46±2.34   6.77±2.22 2.51±1.64 −0.802 <0.001

All values are presented as the mean ± standard deviation. CYLD, cylindromatosis; NA, not applicable; TP, tibial plateau; KL, Kellgren Lawrence.

Association between CYLD expression in the TP and Mankin scores.

CYLD levels (%) I II III IV r P-value
n 27 21 45 63 NA NA
Articular cartilage   6.53±2.01 14.23±4.66 21.13±5.13 38.91±10.82   0.925 <0.001
Subchondral bone 11.46±2.34   7.81±1.66   3.97±1.41 1.73±1.17 −0.844 <0.001

All values are presented as the mean ± standard deviation. CYLD, cylindromatosis; NA, not applicable; TP, tibial plateau.